FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212772365> ?p ?o ?g. }

• W4212772365 endingPage "98" @default.
• W4212772365 startingPage "98" @default.
• W4212772365 abstract "98 Background: P-PSMA-101 is an autologous CAR-T therapy targeting PSMA, with a high percentage of stem cell memory T cells (T SCM ) associated with efficacy, safety, and bone homing (particularly relevant to prostate cancer). It is manufactured using a novel non-viral transposon system (piggyBac) that creates high T SCM products. Genes are inserted encoding a PSMA-targeted Centyrin CAR, iCasp9-based safety switch, and DHFR to purify CAR-T cells. P-PSMA-101 completely eliminated tumors in intractable murine models of prostate cancer, providing rationale for this phase 1 trial (NCT04249947). Methods: Patients with mCRPC treated with or not eligible for a CYP17 inhibitor or second-generation antiandrogen, and a taxane were enrolled. P-PSMA-101 was manufactured from apheresed T cells and administered IV following a standard 3-day cy/flu lymphodepletion regimen. Dose escalation from 0.25-15 x 10 6 cells/kg is planned. Results: As of September 30, 2021, P-PSMA-101 had been administered to 10 heavily pretreated patients (median 7 prior regimens; range 3-15). Single infusions of 0.25 (n=5) to 0.75 (n=5) x 10 6 cells/kg have been assessed, with dose escalation continuing. P-PSMA-101 cells were shown to expand in blood via qPCR assay, peaking 2-3 weeks after infusion, consistent with the high percentage of T SCM . Significant antitumor responses were seen in this preliminary data set. Declines in PSA were seen in 7 patients (>50% in 3 and >99% in 1). Of 4 patients who had pre- and post-treatment FDG and PSMA-PET imaging, 3 demonstrated marked to complete resolution of abnormal uptake at known metastatic disease sites, with concordance in bone and CT scans, and/or circulating tumor cells (CTC). In 1 case, post-treatment tumor biopsy demonstrated infiltration by P-PSMA-101 CAR-T cells and elimination of tumor cells (pathologic complete response). Safety was consistent with expectations for a CAR-T product. CRS was seen in 60% (10% Gr ≥3) of patients. DLT was seen in 1 patient with macrophage activation syndrome/uveitis, and was the only Gr ≥3 CRS event. Immune effector cell-associated neurotoxicity syndrome (ICANS) has not occurred. CRS marker elevations were modest (max IL-6: 642.6 pg/mL). The most common AEs were cytopenias, infections, and constitutional symptoms (Gr ≥3 60%, 10%, and 0%), as expected with lymphodepletion. Treatable related ocular AEs were noted in 3 patients. Conclusions: These results parallel preclinical findings that P-PSMA-101 can produce marked efficacy in mCRPC, and very low doses are highly efficacious, consistent with unique product attributes such as the T SCM phenotype and bone tropism. This is the first report demonstrating profound antitumor effects of a novel PSMA-directed CAR-T-cell platform with concordant biochemical, radiographic, and pathologic parameters, demonstrating that therapeutic benefit of unarmored CAR-T cells in a major solid tumor is possible. Clinical trial information: NCT04249947." @default.
• W4212772365 created "2022-02-24" @default.
• W4212772365 creator A5000933764 @default.
• W4212772365 creator A5014392443 @default.
• W4212772365 creator A5026755682 @default.
• W4212772365 creator A5039147214 @default.
• W4212772365 creator A5040962356 @default.
• W4212772365 creator A5043309004 @default.
• W4212772365 creator A5043368519 @default.
• W4212772365 creator A5053825643 @default.
• W4212772365 creator A5055958896 @default.
• W4212772365 creator A5058325420 @default.
• W4212772365 creator A5058893054 @default.
• W4212772365 creator A5062142470 @default.
• W4212772365 creator A5069777765 @default.
• W4212772365 creator A5077269946 @default.
• W4212772365 creator A5082575811 @default.
• W4212772365 creator A5086609733 @default.
• W4212772365 creator A5091696839 @default.
• W4212772365 date "2022-02-20" @default.
• W4212772365 modified "2023-10-05" @default.
• W4212772365 title "Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W4212772365 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.098" @default.
• W4212772365 hasPublicationYear "2022" @default.
• W4212772365 type Work @default.
• W4212772365 citedByCount "15" @default.
• W4212772365 countsByYear W42127723652022 @default.
• W4212772365 countsByYear W42127723652023 @default.
• W4212772365 crossrefType "journal-article" @default.
• W4212772365 hasAuthorship W4212772365A5000933764 @default.
• W4212772365 hasAuthorship W4212772365A5014392443 @default.
• W4212772365 hasAuthorship W4212772365A5026755682 @default.
• W4212772365 hasAuthorship W4212772365A5039147214 @default.
• W4212772365 hasAuthorship W4212772365A5040962356 @default.
• W4212772365 hasAuthorship W4212772365A5043309004 @default.
• W4212772365 hasAuthorship W4212772365A5043368519 @default.
• W4212772365 hasAuthorship W4212772365A5053825643 @default.
• W4212772365 hasAuthorship W4212772365A5055958896 @default.
• W4212772365 hasAuthorship W4212772365A5058325420 @default.
• W4212772365 hasAuthorship W4212772365A5058893054 @default.
• W4212772365 hasAuthorship W4212772365A5062142470 @default.
• W4212772365 hasAuthorship W4212772365A5069777765 @default.
• W4212772365 hasAuthorship W4212772365A5077269946 @default.
• W4212772365 hasAuthorship W4212772365A5082575811 @default.
• W4212772365 hasAuthorship W4212772365A5086609733 @default.
• W4212772365 hasAuthorship W4212772365A5091696839 @default.
• W4212772365 hasConcept C121608353 @default.
• W4212772365 hasConcept C126322002 @default.
• W4212772365 hasConcept C143998085 @default.
• W4212772365 hasConcept C2777511904 @default.
• W4212772365 hasConcept C2779013556 @default.
• W4212772365 hasConcept C2780192828 @default.
• W4212772365 hasConcept C2781413609 @default.
• W4212772365 hasConcept C502942594 @default.
• W4212772365 hasConcept C530470458 @default.
• W4212772365 hasConcept C61238886 @default.
• W4212772365 hasConcept C71924100 @default.
• W4212772365 hasConceptScore W4212772365C121608353 @default.
• W4212772365 hasConceptScore W4212772365C126322002 @default.
• W4212772365 hasConceptScore W4212772365C143998085 @default.
• W4212772365 hasConceptScore W4212772365C2777511904 @default.
• W4212772365 hasConceptScore W4212772365C2779013556 @default.
• W4212772365 hasConceptScore W4212772365C2780192828 @default.
• W4212772365 hasConceptScore W4212772365C2781413609 @default.
• W4212772365 hasConceptScore W4212772365C502942594 @default.
• W4212772365 hasConceptScore W4212772365C530470458 @default.
• W4212772365 hasConceptScore W4212772365C61238886 @default.
• W4212772365 hasConceptScore W4212772365C71924100 @default.
• W4212772365 hasIssue "6_suppl" @default.
• W4212772365 hasLocation W42127723651 @default.
• W4212772365 hasOpenAccess W4212772365 @default.
• W4212772365 hasPrimaryLocation W42127723651 @default.
• W4212772365 hasRelatedWork W2007917223 @default.
• W4212772365 hasRelatedWork W2085844047 @default.
• W4212772365 hasRelatedWork W2094570582 @default.
• W4212772365 hasRelatedWork W2326416867 @default.
• W4212772365 hasRelatedWork W2502559504 @default.
• W4212772365 hasRelatedWork W2776356588 @default.
• W4212772365 hasRelatedWork W2783882412 @default.
• W4212772365 hasRelatedWork W2810569081 @default.
• W4212772365 hasRelatedWork W2913749717 @default.
• W4212772365 hasRelatedWork W3014214351 @default.
• W4212772365 hasVolume "40" @default.
• W4212772365 isParatext "false" @default.
• W4212772365 isRetracted "false" @default.
• W4212772365 workType "article" @default.